vs

Side-by-side financial comparison of Stagwell Inc (STGW) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

Stagwell Inc is the larger business by last-quarter revenue ($807.4M vs $805.0M, roughly 1.0× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs 2.1%, a 14.3% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs 2.4%). Over the past eight quarters, Stagwell Inc's revenue compounded faster (9.7% CAGR vs 7.6%).

Stagwell Inc., formerly The Stagwell Group, is a global marketing and communications group founded in 2015 by Mark Penn. In 2020, The Stagwell Group announced plans to merge with its affiliate MDC Partners. The merger was completed in August 2021.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

STGW vs WST — Head-to-Head

Bigger by revenue
STGW
STGW
1.0× larger
STGW
$807.4M
$805.0M
WST
Growing faster (revenue YoY)
WST
WST
+5.1% gap
WST
7.5%
2.4%
STGW
Higher net margin
WST
WST
14.3% more per $
WST
16.4%
2.1%
STGW
Faster 2-yr revenue CAGR
STGW
STGW
Annualised
STGW
9.7%
7.6%
WST

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
STGW
STGW
WST
WST
Revenue
$807.4M
$805.0M
Net Profit
$16.8M
$132.1M
Gross Margin
37.8%
Operating Margin
7.0%
19.5%
Net Margin
2.1%
16.4%
Revenue YoY
2.4%
7.5%
Net Profit YoY
460.4%
1.5%
EPS (diluted)
$0.05
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STGW
STGW
WST
WST
Q1 26
$807.4M
Q4 25
$807.4M
$805.0M
Q3 25
$743.0M
$804.6M
Q2 25
$706.8M
$766.5M
Q1 25
$651.7M
$698.0M
Q4 24
$788.7M
$748.8M
Q3 24
$711.3M
$746.9M
Q2 24
$671.2M
$702.1M
Net Profit
STGW
STGW
WST
WST
Q1 26
$16.8M
Q4 25
$12.7M
$132.1M
Q3 25
$24.6M
$140.0M
Q2 25
$-5.3M
$131.8M
Q1 25
$-2.9M
$89.8M
Q4 24
$3.2M
$130.1M
Q3 24
$3.3M
$136.0M
Q2 24
$-3.0M
$111.3M
Gross Margin
STGW
STGW
WST
WST
Q1 26
Q4 25
37.6%
37.8%
Q3 25
36.6%
36.6%
Q2 25
35.0%
35.7%
Q1 25
36.8%
33.2%
Q4 24
36.3%
36.5%
Q3 24
35.7%
35.4%
Q2 24
34.6%
32.8%
Operating Margin
STGW
STGW
WST
WST
Q1 26
7.0%
Q4 25
7.0%
19.5%
Q3 25
8.2%
20.8%
Q2 25
3.3%
20.1%
Q1 25
2.8%
15.3%
Q4 24
5.5%
21.3%
Q3 24
5.9%
21.6%
Q2 24
3.3%
18.0%
Net Margin
STGW
STGW
WST
WST
Q1 26
2.1%
Q4 25
1.6%
16.4%
Q3 25
3.3%
17.4%
Q2 25
-0.7%
17.2%
Q1 25
-0.4%
12.9%
Q4 24
0.4%
17.4%
Q3 24
0.5%
18.2%
Q2 24
-0.4%
15.9%
EPS (diluted)
STGW
STGW
WST
WST
Q1 26
$0.05
Q4 25
$1.82
Q3 25
$1.92
Q2 25
$1.82
Q1 25
$1.23
Q4 24
$1.78
Q3 24
$1.85
Q2 24
$1.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STGW
STGW
WST
WST
Cash + ST InvestmentsLiquidity on hand
$104.5M
$791.3M
Total DebtLower is stronger
$1.3B
$202.8M
Stockholders' EquityBook value
$776.4M
$3.2B
Total Assets
$4.2B
$4.3B
Debt / EquityLower = less leverage
1.71×
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STGW
STGW
WST
WST
Q1 26
$104.5M
Q4 25
$104.5M
$791.3M
Q3 25
$132.2M
$628.5M
Q2 25
$181.3M
$509.7M
Q1 25
$137.7M
$404.2M
Q4 24
$131.3M
$484.6M
Q3 24
$145.8M
$490.9M
Q2 24
$136.1M
$446.2M
Total Debt
STGW
STGW
WST
WST
Q1 26
$1.3B
Q4 25
$1.3B
$202.8M
Q3 25
$1.5B
$202.7M
Q2 25
$1.5B
$202.6M
Q1 25
$1.5B
$202.6M
Q4 24
$1.4B
$202.6M
Q3 24
$1.5B
$202.6M
Q2 24
$1.4B
$205.8M
Stockholders' Equity
STGW
STGW
WST
WST
Q1 26
$776.4M
Q4 25
$758.4M
$3.2B
Q3 25
$749.0M
$3.1B
Q2 25
$750.1M
$2.9B
Q1 25
$334.4M
$2.7B
Q4 24
$331.7M
$2.7B
Q3 24
$286.4M
$2.8B
Q2 24
$291.6M
$2.6B
Total Assets
STGW
STGW
WST
WST
Q1 26
$4.2B
Q4 25
$4.2B
$4.3B
Q3 25
$4.3B
$4.1B
Q2 25
$4.3B
$4.0B
Q1 25
$4.0B
$3.6B
Q4 24
$3.9B
$3.6B
Q3 24
$3.8B
$3.7B
Q2 24
$3.8B
$3.5B
Debt / Equity
STGW
STGW
WST
WST
Q1 26
1.71×
Q4 25
1.75×
0.06×
Q3 25
2.04×
0.07×
Q2 25
1.95×
0.07×
Q1 25
4.38×
0.08×
Q4 24
4.08×
0.08×
Q3 24
5.11×
0.07×
Q2 24
4.88×
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STGW
STGW
WST
WST
Operating Cash FlowLast quarter
$291.0M
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
5.4%
9.5%
Cash ConversionOCF / Net Profit
17.30×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STGW
STGW
WST
WST
Q1 26
$291.0M
Q4 25
$260.3M
$251.1M
Q3 25
$-24.0M
$197.2M
Q2 25
$114.8M
$177.1M
Q1 25
$-60.0M
$129.4M
Q4 24
$212.1M
$190.1M
Q3 24
$-1.6M
$180.1M
Q2 24
$-14.5M
$165.0M
Free Cash Flow
STGW
STGW
WST
WST
Q1 26
Q4 25
$242.9M
$175.0M
Q3 25
$-38.8M
$133.9M
Q2 25
$107.1M
$101.9M
Q1 25
$-63.9M
$58.1M
Q4 24
$209.9M
$85.2M
Q3 24
$-4.3M
$98.8M
Q2 24
$-23.0M
$64.8M
FCF Margin
STGW
STGW
WST
WST
Q1 26
Q4 25
30.1%
21.7%
Q3 25
-5.2%
16.6%
Q2 25
15.1%
13.3%
Q1 25
-9.8%
8.3%
Q4 24
26.6%
11.4%
Q3 24
-0.6%
13.2%
Q2 24
-3.4%
9.2%
Capex Intensity
STGW
STGW
WST
WST
Q1 26
5.4%
Q4 25
2.2%
9.5%
Q3 25
2.0%
7.9%
Q2 25
1.1%
9.8%
Q1 25
0.6%
10.2%
Q4 24
0.3%
14.0%
Q3 24
0.4%
10.9%
Q2 24
1.3%
14.3%
Cash Conversion
STGW
STGW
WST
WST
Q1 26
17.30×
Q4 25
20.56×
1.90×
Q3 25
-0.98×
1.41×
Q2 25
1.34×
Q1 25
1.44×
Q4 24
65.56×
1.46×
Q3 24
-0.49×
1.32×
Q2 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STGW
STGW

Segment breakdown not available.

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons